BioLineRx Ltd. , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December ...
NewtekOne's deposits surged sequentially, with total assets up year-over-year. Click here to see why NEWT stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback